Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease
- 1 December 1994
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 30 (5) , 1187-1194
- https://doi.org/10.1016/0360-3016(94)90327-1
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The management of intractable bone pain: A clinician's perspectiveSeminars in Nuclear Medicine, 1992
- Phosphorus-32 for intractable bony pain from carcinoma of the prostateClinical Oncology, 1990
- A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastasesClinical Oncology, 1989
- Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysisThe British Journal of Radiology, 1987
- Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostateEuropean Journal of Nuclear Medicine and Molecular Imaging, 1986
- Comparison of 32P Therapy and Sequential Hemibody Irradiation (HBI) for Bony Metastases as Methods of Whole Body IrradiationAmerican Journal of Clinical Oncology, 1986
- Dichloromethylene-Diphosphonate in Patients with Prostatic Carcinoma Metastatic to the SkeletonJournal of Urology, 1985
- Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasisCancer, 1985
- Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experienceThe British Journal of Radiology, 1984
- Effective bone palliation as related to various treatment regimensCancer, 1976